text:
Match Marketing Group
"Great company with fabulous field managers "
- Comp & Benefits
- Work/Life Balance
- Senior Management
- Career Opportunities
I have been working at Match Marketing Group
Great communication and support for employees
Reporting system on website is cumbersome and not working well
"Worst run experiential marketing company around "
- Comp & Benefits
- Work/Life Balance
- Senior Management
- Career Opportunities
I worked at Match Marketing Group
ProsThey pay a bit better than Mosaic, but not as well as smaller marketing companies.
Hourly rate is the way to go.
Will hire anyone, you just need a car.
Always need backups because people drop out last minute - a great way to squeeze more money from the hiring staff.ConsHorrible online reporting system that all reps must use. System loses reports and is cumbersome and incredibly time consuming to use.
Management and program launches are incredibly disorganized.
Very little support for reps. Management talks to reps like children.
Very high turnover rate for Area Managers.
Pay can get missed if managers do not approve on time, or miss online reports.
No guarantees that you can get lost or missed pay if you don't catch the fact they missed paying you in time.Doesn't Recommend -
2 people found this helpful
"Vampires and Match Marketing Have a Lot in Common "
- Comp & Benefits
- Work/Life Balance
- Senior Management
- Career Opportunities
I have been working at Match Marketing Group
ProsExperiential marketing gets you onto the front lines of consumer behavior and insight into the competitive world of brand marketing. For a price.
ConsWork more than you get paid for as a rule. Constantly be on guard to monitor your paycheck to see if you were paid for all the hours submitted. Bank roll the company for your out of pocket expenses and gas and hope that someone remembered to approve them. Get no respect or appreciation for anything you do as a brand ambassador for the company. Management is always looking for faults in performance, people to blame, ways to not pay you. You are considered disposable. Be threatened with termination for any reason.
Don't put yourself out there long term for them...not worth the rate of return.Advice to ManagementAdviceToo many intimidation tactics and control issues going on at head office-- Scary vampires.
Doesn't Recommend -


text:
Atwater man gets probation, treatment orders for March assault
WILLMAR — Cody James Michael Hinman, 22, of Atwater, was sentenced Wednesday to seven years of probation, 73 days in jail, a $50 fine and 60 hours of community service on a felony charge of second-degree assault for pointing a shotgun at a woman in March.
Get the full story
Subscribe or Log In
Are you a newspaper subscriber but you don't have a Digital Access account yet? Activate your account.
You will need your subscription account number and phone number. Not sure if you have an account? Email us or call 320-214-4364 and we can help you.

subset: commoncrawl


text:
Talk:A Town Like Alice
WikiProject Australia / Northern Territory | (Rated Start-class) | |||||||||||||||||||||||||
WikiProject Novels | (Rated Start-class, Mid-importance) | |||||||||||||||||||
U.S. title: The Legacy[edit]
Is the book still being published under the title 'the legacy' in the US or is it now being published under the title 'a town like alice'? PicBook (talk) 14:32, 29 October 2008 (UTC)
Minor cleanup[edit]
Fixed a couple of typos and suchlike. 17:46, 16 November 2008 (UTC+1) —Preceding unsigned comment added by 18.104.22.168 (talk)
I believe the film portion of the article should have it's own article. Anyone agree? Andrzejbanas (talk) 16:55, 2 November 2009 (UTC)
Sexist desciption of themes[edit]
It is presumed that a male lawyer is chosen to oversee the money of a woman. The two assumptions being that a woman solicitor was deliberately not chosen, and that a man would not have his inheritance tied up in a trust. Unless the book states that either are the case, the assumption of gender bias is just that, an assumption - which is itself sexist. In the 1930's there were very few female solicitors in London, or anywhere. It was normal, and remains normal, for large estates to be tied up in trusts till the beneficiary reaches a certain age. Irrespective of sex. The ploy of the book is thus not sexist, and quite normal. — Preceding unsigned comment added by 220.127.116.11 (talk) 01:20, 29 May 2011 (UTC)
- Start-Class Australia articles
- Unknown-importance Australia articles
- Start-Class Northern Territory articles
- Unknown-importance Northern Territory articles
- WikiProject Northern Territory articles
- WikiProject Australia articles
- Start-Class novel articles
- Mid-importance novel articles
- Start-Class Military fiction task force articles
- Unknown-importance Military fiction task force articles


text:
StartUpHire is the place to find jobs at South Bend startups. Review the list of South Bend career opportunities to the left. These South Bend, IN jobs at startups represent some of the most rewarding careers available.
You can refine your job search for South Bend career opportunities by adding a job title, company name, or keyword to the search box above … or click the "Advanced Search" link for more options.
Don't see the employment opportunity you're looking for? Check back soon for more startup jobs in South Bend, or sign up for an email alert (link below) to receive periodic updates on new start up jobs in South Bend, IN.
Site : D.C. Cook Nuclear Power Plant Location : Bridgman MI US 49106 Education : Bachelors Skill : Information Technology -> Database Administrator Category : Professional Job Description : The Database Developer/Administrator designs, modifies, develops, writes and implements
1/14/2015 Bridgman, MI Save This Job


text:
P.A. Governor Tom Corbett: Joe Paterno 'Probably' Shouldn't Have Been Fired
Though he reportedly pushed for his dismissal.
READ MORE »Though he reportedly pushed for his dismissal.
READ MORE »The second one this week.
READ MORE »Officials say he hit her because she soiled her pants.
READ MORE »On Twitter.
READ MORE »More details about the accusations have odd echoes in the actor's past work.
READ MORE »Most Americans are cool with corporal punishment.
READ MORE »Her father and stepmother are finally in jail after nearly two years of beatings.
READ MORE »The convicted Penn State abuser's wife is still in denial.
READ MORE »Prosecutors say murder charges are likely.
READ MORE »Ultimately, what you think depends on whose experience you identify with more.
READ MORE »The Internet continues to dig up disturbing stories in light of the resurfaced child-molestation allegations.
READ MORE »"I felt he was in reasonable care," said Wade.
READ MORE »Just awful.
READ MORE »The legendary radio host was dealing with an undercover cop.
READ MORE »"My daddy punched me in the face."
READ MORE »Jose Ramos served 25 years for unrelated child molestation convictions.
READ MORE »Timothy Dolan took to the pulpit to speak up for his boss.


text:
It's time to ride! April is Valley Bike Month and the perfect time to be outside. Save money on gas, reduce air pollution and stay healthy by riding your bike to work, school, on errands or just for fun. In celebration of Valley Bike Month, the City of Mesa is having two events for bike riders.
The City of Mesa will celebrate Bike2Work Day on April 22, 2015 from 6:00 - 8:00 a.m. Ride your bicycle to Mesa City Plaza and meet up with other cyclists, enjoy a hot fundraiser breakfast (fee) and informational booths. Everyone is invited, even those who are not cyclists.
If you have any questions call 480.644.3219


text:
Strapless A-line Alyce Paris 35576 White Prom Dresses with Jeweled Belt
A-Line sweetheart Silk Chiffon Alyce Paris B'Dazzle 35576 dress. Asymmetrical pleated bodice with natural waistline and crystal beaded belt. This dress is perfect as a Homecoming Dress, Wedding Guest Dress, Prom Dress, or a Special Occasion Dress.
Style: AL-35576
Closure: Back Zipper
Details: Ruched Bodice, Beaded Waist
Fabric: Chiffon
Length: Long
Neckline: Strapless Sweetheart
Waistline: Natural
Tag: Prom Dresses,Homecoming Dresses,Evening Dresses,Alyce Paris 35576
Alyce Paris 35576 Prom Dresses
On January 22 2015 at Hong Kong 41 Views


text:
Forgot password? | Create an Account
Home > Geek Toys > R/C Toys >
So that's how you feel about the holidays!
Maxx does not approve of censorship
Holy flying f*ck, Batman!
Censorship kitteh does not approve
The highlight of the white elephant exchange
Airzooka Air Gun
Screaming Monkey Slingshot


text:
Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
ABSTRACT To evaluate the efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging (MRI)-determined early sacroiliitis, using both clinical and MRI assessments.
Forty patients with recent-onset inflammatory back pain, as assessed by the Calin criteria, HLA-B27 positivity, clinical disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain and morning stiffness, and magnetic resonance imaging (MRI)-determined sacroiliac joint bone edema were randomized in a double-blind manner to receive infliximab 5 mg/kg or placebo at 0, 2, 6, and 12 weeks. MRI scans were performed at baseline and 16 weeks and scored by 2 observers (blinded to both the order of the scans and to treatment group), using the Leeds scoring system. Clinical assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group criteria (ASAS) for improvement, and markers of inflammation.
The mean reduction in the total MRI score from week 0 to week 16 was significantly greater in infliximab-treated patients compared with placebo-treated patients (P = 0.033). On average, significantly more lesions resolved in the infliximab group (P < 0.001), while significantly more new lesions developed in the placebo group (P = 0.004). Significantly greater improvement in the infliximab group versus the placebo group was also observed for changes from week 0 to week 16 in the BASDAI (P = 0.002), BASFI (P = 0.004), and ASQoL (P = 0.007) scores. Responses according to the ASAS criteria for 40% improvement, the ASAS criteria for 20% improvement in 5 of 6 domains, and ASAS partial remission were achieved by 61%, 44%, and 56% of infliximab-treated patients, respectively. Infliximab was well tolerated, and no serious adverse events were observed.
Infliximab was an effective therapy for early sacroiliitis, providing a reduction in disease activity by week 16. This study is the first to show that infliximab is effective for reducing clinical and imaging evidence of disease activity in patients with MRI-determined early axial spondylarthritis.
- Zeitschrift für Rheumatologie 09/2014; 73 Suppl 2:78-96. · 0.46 Impact Factor
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Ankylosing spondylitis (AS) is a chronic inflammatory disease with prominent involvement of the spine and sacroiliac joints which frequently leads to significant spine deformity and disability. The development of effective therapies for AS, particularly with anti-tumor necrosis factor agents, has resulted in improved symptoms and functions for many patients, and clinical research increasingly suggests that effective therapy can also prevent destruction in the spine and other structures. Recent focus of disease classification in AS has emphasized that many individuals with features of inflammatory back pain but no visible changes on plain x-rays have active inflammatory disease when imaged with magnetic resonance imaging (MRI). Recent studies indicate that individuals with "non-radiographic" spondylitis can also respond to anti-inflammatory therapies. Several new agents are also showing promise for treatment of AS. These developments represent a significant advance in the management of this debilitating condition.F1000prime reports. 09/2014; 6:78. - Arthritis & Rheumatology 08/2013; 65(8). · 7.48 Impact Factor
Page 1
Vol. 60, No. 4, April 2009, pp 946–954
DOI 10.1002/art.24408
© 2009, American College of Rheumatology
Clinical and Imaging Efficacy of Infliximab in
HLA–B27–Positive Patients With Magnetic
Resonance Imaging–Determined Early Sacroiliitis
Nick Barkham, Helen I. Keen, Laura C. Coates, Philip O'Connor, Elizabeth Hensor,
Alexander D. Fraser, Lorna S. Cawkwell, Alexander Bennett,
Dennis McGonagle, and Paul Emery
Objective. To evaluate the efficacy of infliximab in
HLA–B27–positive patients with magnetic resonance
imaging (MRI)–determined early sacroiliitis, using
both clinical and MRI assessments.
Methods. Forty patients with recent-onset inflam-
matory back pain, as assessed by the Calin criteria,
HLA–B27 positivity, clinical disease activity as mea-
sured by the Bath Ankylosing Spondylitis Disease Ac-
tivity Index (BASDAI), pain and morning stiffness, and
magnetic resonance imaging (MRI)–determined sacro-
iliac joint bone edema were randomized in a double-
blind manner to receive infliximab 5 mg/kg or placebo
at 0, 2, 6, and 12 weeks. MRI scans were performed at
baseline and 16 weeks and scored by 2 observers
(blinded to both the order of the scans and to treatment
group), using the Leeds scoring system. Clinical assess-
ments included the BASDAI, the Bath Ankylosing
Spondylitis Functional Index (BASFI), the Ankylosing
Spondylitis Quality of Life (ASQoL) instrument, the
ASsessment in Ankylosing Spondylitis International
Working Group criteria (ASAS) for improvement, and
markers of inflammation.
Results. The mean reduction in the total MRI
score from week 0 to week 16 was significantly greater in
infliximab-treated patients compared with placebo-
treated patients (P ? 0.033). On average, significantly
more lesions resolved in the infliximab group (P <
0.001), while significantly more new lesions developed in
the placebo group (P ? 0.004). Significantly greater
improvement in the infliximab group versus the placebo
group was also observed for changes from week 0 to
week 16 in the BASDAI (P ? 0.002), BASFI (P ? 0.004),
and ASQoL (P ? 0.007) scores. Responses according to
the ASAS criteria for 40% improvement, the ASAS
criteria for 20% improvement in 5 of 6 domains, and
ASAS partial remission were achieved by 61%, 44%, and
56% of infliximab-treated patients, respectively. Inflix-
imab was well tolerated, and no serious adverse events
were observed.
Conclusion. Infliximab was an effective therapy
for early sacroiliitis, providing a reduction in disease
activity by week 16. This study is the first to show that
infliximab is effective for reducing clinical and imaging
evidence of disease activity in patients with MRI-
determined early axial spondylarthritis.
Ankylosing spondylitis (AS), the prototype spon-
dylarthritis (SpA), is increasingly recognized as an im-
portant and potentially treatable condition. AS is more
common than previously estimated, with some studies
suggesting a prevalence similar to that of rheumatoid
European Clinical Trials (EudraCT) Database: 2004-001880-
23, DDX No MS8000MN/13157.
Supported by Centocor, which also provided the study drug.
Nick Barkham, MBChB, MRCP, Helen I. Keen, MBBS,
FRACP, Laura C. Coates, MBChB, Philip O'Connor, FRCR, Eliza-
beth Hensor, PhD, Alexander D. Fraser, MD, FRCPI, Lorna S.
Cawkwell, MRCP, Alexander Bennett, MBChB, MRCP, Dennis
McGonagle, PhD, MRCPI, Paul Emery, MA, MD, FRCP: University
of Leeds, Leeds, UK.
Dr. Barkham has received speaking fees and a travel grant
(less than $10,000 each) from Centocor; the University of Leeds unit
within which he works has received research funding from Centocor.
Dr. Keen has received a travel grant from Schering-Plough (less than
$10,000). Dr. Coates has received consulting fees, speaking fees,
and/or honoraria from Schering-Plough (less than $10,000). Dr. Emery
has received consulting fees, speaking fees, and/or honoraria from
Schering-Plough, Centocor, Wyeth/Amgen, Abbott, Roche, and
Bristol-Myers Squibb (less than $10,000 each).
Address correspondence and reprint requests to Paul Emery,
MA, MD, FRCP, Academic Unit of Musculoskeletal Disease, Chapel
Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail:
Submitted for publication May 13, 2008; accepted in revised
form December 30, 2008.
Page 2
arthritis (1). Importantly, AS affects individuals at a time
when they are economically active (most commonly in
the third decade of life), and the disease has a major
impact on their ability to work (2).
Anecdotal evidence has suggested that patients
who are treated early, i.e., before radiographic changes
are apparent, have a better outcome (3). However, the
current diagnosis of AS according to the modified New
York criteria (4) relies on radiographically detectable
damage. Therefore, the definitive diagnosis of AS is
often delayed by up to a decade, because this is the
length of time that may be required for structural
changes to develop (5).
The limitations of radiography have been par-
tially addressed by the advent of fat-suppressed mag-
netic resonance imaging (MRI), which can be used to
diagnose axial SpA at a stage when radiographic findings
remain normal (6). Histologic studies have confirmed
that these early MRI changes are caused by osteitis at
the sacroiliac joints (7,8) and typically evolve into radio-
graphic AS over several years (9).
One of the great challenges in caring for patients
with AS is early and accurate diagnosis. The Calin
criteria for diagnosis of early inflammatory back pain
(10) lack sensitivity and specificity (11,12). A recently
proposed modification of the clinical criteria (13) has
been shown to have much greater sensitivity and speci-
ficity but has not been tested in early disease. In
addition, the serum level of markers of inflammation are
not consistently elevated in these patients and thus are
not reliable surrogate markers for diagnosis (14,15).
Based on the strong association between HLA–
B27 positivity and AS, testing patients with early inflam-
matory back symptoms for HLA–B27 is useful for early
diagnosis as well as for predicting persistent disease that
may be associated with ocular and cardiac manifesta-
tions (16). Indeed, the combination of the Calin criteria
for inflammatory back pain, HLA–B27 positivity, and
MRI-defined early sacroiliitis identifies a group of pa-
tients who could experience progression to AS in ?90%
of cases (17).
The advent of anti–tumor necrosis factor (anti-
TNF) antibodies in the field of rheumatology has pro-
vided new therapeutic options for patients with AS. The
efficacy of anti-TNF therapies in AS has been confirmed
in numerous trials (18–21). However, until now, there
has been no evidence to justify treatment of MRI-
determined early axial SpA with anti-TNF agents, be-
cause all of the randomized controlled trials conducted
to date (18–21) have used diagnosis according to the
definite modified New York criteria (4) for inclusion. In
the present study, we combined the Calin criteria for
inflammatory back pain, HLA–B27 positivity, and MRI-
defined early sacroiliitis to identify a homogeneous
cohort of patients with early axial SpA in whom disease
would likely progress to AS and randomized these
patients to receive infliximab therapy or placebo, in
order to ascertain the effectiveness of anti-TNF therapy
in patients with preradiographic axial SpA.
The trial was conducted at the Leeds Teaching Hospi-
tals Trust, Leeds, UK. The local ethics committee approved
the study, and written informed consent was obtained from all
patients prior to screening.
Inclusion and exclusion criteria. Eligible patients had
a combination of inflammatory back pain, according to the
Calin criteria (10), for the previous 3 months to 3 years (Table
1), were positive for HLA–B27, and had MRI evidence of
sacroiliitis. All eligible patients had active disease, as defined
by at least 2 of the following: a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) score of ?40, a pain score of
?40 on a 100-mm visual analog scale, and early morning
stiffness lasting ?45 minutes. From studies of infliximab
treatment in established AS with MRI outcome (22), we
calculated that at the 5% significance level with 80% power
detecting a 50% difference between the placebo and treatment
groups in the mean changes from baseline to the end point, 20
patients were required in each group.
To identify 40 patients with MRI-determined sacroiliac
joint bone edema, 49 patients with symptoms and HLA–B27
positivity were screened and underwent MRI. The MRIs were
reviewed by musculoskeletal radiologists for the presence of
sacroiliac joint bone marrow edema representative of active
sacroiliitis. Nine patients had no evidence of sacroiliac joint
bone edema on MRI and were therefore not randomized into
the study. Other exclusion criteria were past or current tuber-
Table 1.
the criteria described by Calin et al (ref. 10)*
Working definition of inflammatory back pain, according to
Age at onset of back discomfort, years
Not insidious
Persistence of back discomfort, months
Associated with morning stiffness
Response to exercise
No improvement
* A score of ?4 indicates the presence of inflammatory back pain.
Page 3
culosis, congestive heart disease, treatment with systemic glu-
cocorticoids in the previous month, and treatment of the
sacroiliac joints with intraarticular glucocorticoids within the
previous 3 months.
Treatment protocol. Patients fulfilling the inclusion
criteria were randomized to receive infusions of placebo or
infliximab (5 mg/kg) at 0, 2, 6, and 12 weeks. Treatment with
oral nonsteroidal antiinflammatory drugs remained unchanged
throughout the study. Intraarticular steroid therapy was not
allowed, nor was the introduction of oral glucocorticoids or
disease-modifying antirheumatic drugs.
Study assessments. The efficacy of therapy was deter-
mined by evaluating changes in MRI and clinical/functional
assessments. The primary study end point was the change in
the total MRI score (sum of the 8 sacroiliac joint regions) from
week 0 to week 16. Safety was assessed by monitoring patients
for the occurrence of adverse events and by collecting samples
for clinical laboratory testing at each visit.
MRI protocol and scoring. MRI scans were performed
at baseline (week 0) and week 16, using the commercially
available 1.5T Gyroscan ACS-NT system (Philips, Best, The
Netherlands). Patients were examined in the supine position,
with a flat-surface coil positioned under the sacrum. T1-
weighted turbo spin-echo (TSE) and STIR TSE fat-suppressed
coronal oblique sequences of the sacroiliac joints and T2-
weighted spectral presaturation with inversion recovery sagit-
tal sequences of the whole spine were obtained. The MRI
parameters were as follows: for T1-weighted oblique se-
quences of the sacroiliac joint, repetition time (TR) 892 msec,
time to echo (TE) 14 msec, matrix 384 ? 512 pixels, field of
view (FOV) 320 mm, slice thickness 4.0 mm, slice gap 0.4 mm,
number of signals averaged (NSA) 3, and acquisition time 5
minutes 44 seconds; for STIR TSE, TR 2,500 msec, TE 10
msec, matrix 382 ? 512 pixels, FOV 320 mm, slice thickness 4.0
mm, slice gap 0.8 mm, NSA 2, and acquisition time 4 minutes
35 seconds.
The pretreatment and posttreatment scans were scored
together simultaneously by 2 independent observers (DM and
LCC) who were blinded to both the order of the scans and to
treatment group, using a previously reported scoring system
(3,22). Observer disagreement was resolved by consensus.
Regions of MRI-determined sacroiliitis, as defined on T2-
weighted fat-suppressed images as bone marrow edema (iden-
tified by a high or intermediate marrow signal), were scored.
For scoring purposes, the sacroiliiac joint was split into 8
regions, as previously described (22). Briefly, a line was drawn
across the upper third of the sacroiliac joint, and the upper
right iliac, upper right sacral, upper left sacral, and upper left
iliac regions were evaluated. The 4 corresponding lower re-
gions were similarly evaluated. Each region was scored for
bone edema as follows: 0 ? absent, 1 ? mild, 2 ? moderate,
and 3 ? extensive. The scores were based on both the extent of
osteitis and its severity (or intensity). An overall score of
inflammatory activity was calculated as the sum of scores for
bone marrow edema, for a total possible maximal score of 12
per joint (24 per patient). To assess the degree of change
between scans, paired scoring was performed for every lesion
using this system with, for example, resolution of a severe
lesion improving from a score of 3 to a score of 0. In the spine,
bone marrow lesions were defined as described above and
were recorded as present or absent in the vertebral body,
posterior elements including spinous processes and facet
joints, and paraspinal soft tissues. A total count of lesions per
spinal area for each patient was performed. Change was
assessed as resolution of the baseline lesions.
Radiographic assessments. Radiography of the sacro-
iliac joints was not routinely performed as part of the study
protocol. However, the majority of patients did undergo
radiography of the sacroiliac joints just prior to being screened
for the study. These radiographs were reviewed by indepen-
dent radiologists/rheumatologists who were blinded to the
treatment group and MRI findings.
Clinical and functional assessments. At each visit, dis-
ease activity was assessed with the BASDAI (23), the physi-
cian's global assessment of disease activity, and the swollen and
tender joint counts (n ? 28) to assess peripheral involvement.
The Bath Ankylosing Spondylitis Functional Index (BASFI)
(24), the disability index of the Health Assessment Question-
naire (HAQ) (25), and the Ankylosing Spondylitis Quality of
Life instrument (ASQoL) (26) were used to assess function,
disability, and quality of life at each visit. Also at each visit,
spinal mobility was assessed by the measurement of chest
expansion and the Schober test of lumbar flexion. Samples
were collected at each visit for determination of the erythro-
cyte sedimentation rate (ESR) and the C-reactive protein
(CRP) level, both of which are markers of inflammation. The
ASsessment in Ankylosing Spondylitis International Working
Group criteria for 40% improvement (ASAS40) (27), 20%
improvement in 5 of 6 domains (27), and for partial remission
(28) were applied to these clinical data.
Statistical analysis. Data were summarized and tested
according to distribution and type. Means and standard devi-
ations are presented for normally distributed continuous data,
and Student's t-tests were used to compare the 2 treatment
groups. Medians and interquartile ranges were presented for
non-normally distributed and ordinal data, which were com-
pared with nonparametric Mann-Whitney U tests. Nominal
data were summarized as the number (%) and compared with
Pearson's chi-square tests, continuity-corrected as appropriate
if the expected cell count dropped below 5. All tests were
performed at the 5% level of significance. Corrections for
multiple testing within each family of statistical tests were
applied for secondary outcomes, according to Holm's modifi-
cation of the Bonferroni adjustment. The following thresholds
for statistical significance of secondary outcomes were derived:
for the Mann-Whitney U test, 0.007; for Student's t-test, 0.025;
for the chi-square test, 0.017. All analyses were performed
using SPSS software version 15.1.1 (SPSS, Chicago, IL).
Patient demographics. Forty patients were ran-
domized (20 to infliximab treatment and 20 to the
placebo group). One patient (in the placebo group)
withdrew consent at 12 weeks and discontinued partici-
pation in the study. This patient was included in the
analysis of efficacy, because it was performed on an
intent-to-treat basis. The remaining 39 patients com-
pleted the study. The randomized treatment groups
Page 4
were similar with regard to baseline demographic and
disease characteristics (Table 2). Despite an average
duration of back pain of ?1–1.5 years, patients had
evidence of active disease (mean BASDAI score ?5.5),
causing significant impairment of functional ability and
quality of life. Associated extraarticular features in-
cluded iritis in 6 patients (15%), psoriasis in 4 patients
(10%), and inflammatory bowel disease in 1 patient
(2.5%). Three patients (7.5%) had a family history of
AS, 6 patients (15%) had a family history of psoriasis,
and 4 patients (10%) had a family history of inflamma-
tory bowel disease.
MRI findings. Thirty-nine patients (20 in the
infliximab group and 19 in the placebo group) had MRI
performed at baseline and week 16. One patient did not
have a repeat scan at 16 weeks because he had with-
drawn consent at 12 weeks; the last observation carried
forward was used for analysis in his case. All patients had
lesions on baseline MRI scans consistent with active
disease, when reviewed by musculoskeletal radiologists
prior to entry into the study. When blinded paired
scoring of the scans was performed after the study, 3
patients (all in the placebo group) had a baseline MRI
score of 0. The remainder of the patients all had scores
of grade 1 or higher. Seventy percent of the patients had
bilateral sacroiliitis. The median total MRI score for the
sacroiliac joints at baseline was 3.5 (interquartile range
[IQR] 2, 8), and the median changes at week 16 were 0
(IQR –2.00, 1.50) in the placebo group and ?2.00 (IQR
?6.25, 0.00) in the infliximab group (for the primary end
point, Mann-Whitney U asymptotic z ? ?2.17, P ?
0.033). None of the patients in the infliximab group had
an increase in the total MRI score, whereas 5 patients in
the placebo group did have such an increase.
At baseline, 75 and 60 abnormal sacroiliac joint
lesions were observed in the infliximab group and the
placebo group, respectively. Among the abnormal base-
line joint regions (score ?1), 47 (62.7%) in the inflix-
imab group resolved completely, versus 20 (29.4%) in
the placebo group (Pearson's ?2? 15.84, 1 df, P ?
0.001). When considering joint regions with moderate or
high levels of inflammation (MRI score ?2) at baseline
(24 in the placebo group and 22 in the infliximab group),
6 (22.2%) in the placebo group resolved completely,
compared with 17 (77.3%) in the infliximab group
(Pearson's ?2? 14.75, df ? 1, P ? 0.001).
Considering those regions with no MRI abnor-
mality at baseline (MRI score ? 0), 92 sacroiliac joint
regions in the placebo group (57.5%) were normal,
compared with 85 sacroiliac joint regions in the inflix-
imab group (53.1%) (P ? 0.431, by chi-square test).
Among these normal joint regions, new lesions devel-
oped in 11 (12.0%) in the placebo group compared with
1 (1.2%) in the infliximab group (Pearson's ?2? 8.12,
1 df, P ? 0.004).
Patients with moderate or extensive bone marrow
edema (at least 1 sacroiliac region with a score of grade
?2) were compared with those with mild edema only (all
regions scoring grade 1). In the placebo group, there was
no significant difference in the MRI response (change in
total lesion score) between patients with mild baseline
bone edema (median 1, IQR ?2, 3) and those with
moderate or extensive edema (median ?0.5, IQR
?5.25, 0; P ? 0.475, by Mann-Whitney U test). In the
infliximab group, patients with mild baseline bone
edema showed significantly less improvement in the
total MRI score (median 0.0, IQR ?2.0, 0.0) than those
with moderate or extensive edema (median ?7, IQR
Although all patients manifested baseline sacro-
iliac joint inflammation, only 9 patients (22.5%; 5 in the
infliximab group and 4 in the placebo group) had
inflammation detectable on spinal MRI scans. Among
patients with spinal inflammation, an average of 3 (range
1–6) spinal lesions were present. Three of the 5
infliximab-treated patients with spinal lesions had com-
plete resolution (10 of 12 lesions resolved), compared
Table 2.
Baseline characteristics of the patients*
(n ? 20)
(n ? 20)
No. of men/no. of women
Age, mean years
Mean duration of back pain, months
Mean BASFI score
Mean BASDAI score
CRP, mg/liter
HAQ score (range 0–3)
ASQoL score (range 0–18)
Chest expansion, mm
Lumbar flexion, mm
Concomitant NSAID use, no. (%)
of patients
Mean number of SI joint lesions
on MRI
18 (90)
18 (90)
* Except where indicated otherwise, values are the median. For
C-reactive protein (CRP), n ? 18 patients in the placebo group and 19
patients in the infliximab group. For the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) score, n ? 19 patients in the placebo
group. No significant differences between placebo and infliximab were
observed for any of the variables. BASFI ? Bath Ankylosing Spondy-
litis Functional Index; HAQ ? Health Assessment Questionnaire;
ASQoL ? Ankylosing Spondylitis Quality of Life; NSAID ? nonste-
roidal antiinflammatory drug; SI ? sacroiliac; MRI ? magnetic
resonance imaging.
Page 5
with 1 of 4 patients in the placebo group (4 of 14 lesions
resolved) (P ? 0.016).
Plain radiography findings. In 34 of 40 patients,
plain radiographs of the sacroiliac joints were obtained
at baseline. Sixteen (47%) of the 34 radiographs were
entirely normal, 14 (41%) of the 34 radiographs showed
minor abnormalities not sufficient to make a diagnosis
according to the modified New York criteria, and 4
(12%) of the 34 radiographs fulfilled the modified New
York criteria for a radiographic diagnosis of AS.
Results of clinical and functional assessments.
The week 16 findings for clinical and functional assess-
ments are summarized in Table 3. The mean reduction
in the BASDAI score at 16 weeks was significantly
greater in the infliximab group (?3.41) than in the
placebo group (?0.75) (P ? 0.002). Functional ability,
as assessed by the BASFI score, also improved to a
significantly greater extent in the infliximab group
(mean reduction ?2.70) compared with the placebo
group (mean reduction ?0.47) (P ? 0.004). There was
no significant difference between treatment groups in
CRP level reductions; however, baseline CRP levels of
11.5 mg/liter in the placebo group and 5.0 mg/liter in the
infliximab group likely precluded detection of a
treatment-related difference. There was a trend toward
a larger reduction in the HAQ disability index score
among infliximab-treated patients (?0.44) compared
with placebo-treated patients (?0.13), but this differ-
ence did not reach significance (P ? 0.065). There was,
however, significant improvement in quality of life by 16
weeks, as measured by the ASQoL score, in infliximab-
treated patients (?6.18) compared with placebo-treated
patients (?1.00) (P ? 0.007).
In terms of the composite ASAS response crite-
ria, significantly larger proportions of infliximab-treated
patients than placebo-treated patients met the ASAS40
criteria (61.1% versus 17.6%; P ? 0.009) for improve-
ment at week 16 (Table 3.) In addition, more than half
of infliximab-treated patients (55.6%) met the ASAS
partial remission criteria at week 16, compared with
12.5% of placebo-treated patients (P ? 0.009) (Table 3).
There was no significant difference in the placebo
or treatment arm in changes in the BASDAI score
between patients with mild baseline MRI bone edema
(score ?1) and those with moderate or severe baseline
MRI bone edema (P ? 0.68 in the placebo group and
P ? 0.71 in the infliximab group). In the infliximab
group, a higher proportion of patients with an elevated
line CRP level (n ? 9) achieved all of the ASAS
composite measures, compared with those patients (n ?
9) with a normal baseline CRP level (for ASAS20, 8
patients versus 6 patients; for ASAS50, 7 patients versus
4 patients; for ASAS70, 6 patients versus 4 patients).
However, this difference was not shown to be statistically
significant, due to the small numbers of patients in these
Adverse events. Study medication was well toler-
ated, and no serious adverse events were observed. An
allergy to infliximab, characterized by a rash and bron-
chospasm, developed in 1 patient in the infliximab
group. This patient discontinued infliximab therapy at
week 6 but continued in the study and had a followup
MRI performed at week 16.
TNF blockade has been a crucial advance in the
treatment of AS in recent years. However, previous
Table 3.
Results of clinical and functional assessments at week 16*
(n ? 20)
(n ? 20)P
BASDAI score, mean ? SD
BASFI score, mean ? SD
C-reactive protein, mg/liter
HAQ disability index score
Chest expansion
Lumbar flexion, cm
ASQoL score
ASAS40 response, no./no. tested (%)
ASAS5/6 response, no./no. tested (%)
ASAS partial remission, no./no. tested (%)
?0.75 ? 2.42
?0.47 ? 2.25
?1.5 (?6.6, 0.5)
?0.13 (?0.38, 0.00)
0.000 (?1.000, 1.500)
0.00 (?0.50, 1.00)
?1.00 (?4.50, 0.75)
3/17 (17.6)
2/15 (13.3)
2/16 (12.5)
?3.41 ? 2.53
?2.70 ? 2.36
?4.0 (?10.0, 0.0)
?0.44 (?0.93, ?0.13)
1.000 (0.000, 1.875)
0.50 (0.00, 1.00)
?6.18 (?10.00, ?2.25)
11/18 (61.1)
8/18 (44.4)
10/18 (55.6)
* Except where indicated otherwise, values are the median (interquartile range). For the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), chest expansion, and lumbar flexion, n ? 19 patients in the placebo group. For C-reactive protein,
n ? 18 patients in the placebo group and 19 patients in the infliximab group. BASFI ? Bath Ankylosing Spondylitis Functional
Index; HAQ ? Health Assessment Questionnaire; ASQoL ? Ankylosing Spondylitis Quality of Life; ASAS40 ? ASsessment
in Ankylosing Spondylitis International Working Group criteria for 40% improvement.
Page 6
studies have been limited to patients in whom the
diagnosis of AS was confirmed by the definite modified
New York criteria, which rely on the presence of radio-
graphic structural changes, which can take several years
to develop. In this study, we used stringent inclusion
criteria to identify a homogeneous cohort of HLA–B27–
positive patients with MRI-determined sacroiliitis who
have early axial SpA and a high likelihood of eventually
progressing to radiographically defined AS. In this co-
hort, infliximab therapy resulted in significant sup-
pression of MRI-determined inflammation relative to
placebo, with a significant reduction in the total MRI
score, increased resolution of inflammatory lesions, and
decreased progression of new inflammatory lesions at
week 16 (Figure 1). These results are consistent with
those seen in patients with established AS (18,22,29).
Additionally, we observed impressive clinical responses
to infliximab therapy, with improvement in disease ac-
tivity, functional status, and quality of life seen at
week 16.
When comparing our findings with those derived
from a study of infliximab in established AS (20), the
proportion of patients reaching the ASAS partial remis-
sion criteria was far higher (55.6% versus 22.4%), sug-
gesting a clear benefit for early treatment of apparently
more reversible disease. Previous studies in established
AS have shown that patients with a shorter disease
duration have a better response to anti-TNF agents (30),
suggesting that very early treatment before damage is
evident on radiographs will lead to improved responses.
Therefore, this study confirms the efficacy of infliximab
in early axial SpA and suggests that these patients may
respond more favorably to infliximab treatment than
patients with radiographically evident, established AS
As noted, the lack of a significant treatment
effect on reductions in CRP levels is likely attributable
to a low median baseline CRP level of 5 mg/liter in the
infliximab group. It is known that CRP levels can be
variable in AS, with some patients showing very little
systemic inflammatory response (14,15). It appears that
in the early stages of disease that characterized our study
cohort, a higher proportion of patients will have normal
levels of markers of inflammation, and that these mark-
ers cannot be relied on to aid diagnosis or guide therapy.
The results suggested a better response in those individ-
uals with an elevated baseline CRP level; however,
patients with a normal CRP level did respond to inflix-
imab, with two-thirds of patients achieving an ASAS20
These patients represent a select group of those
presenting with inflammatory low back pain, having a
relatively brief symptom duration and active disease
both clinically and on MRI. Their disease was impacting
their functional ability and quality of life, and no current
proven treatment options were available to them. Given
that the average age of the patients was younger than 30
years, the majority were working full-time. However,
many were struggling to cope because of their disease.
Until now, there has been no evidence to guide the
treatment of such patients. Current guidelines on the
treatment of AS are all based on a diagnosis according to
definite New York criteria, which require radiographic
evidence of disease (31). This study provides novel data
on the clinical and MRI-determined efficacy of TNF
blockade in HLA–B27–positive patients with active sac-
roiliitis. Of note, patients with HLA–B27–positive in-
flammatory back pain without MRI-defined osteitis
were excluded from this study. The role of anti-TNF
agents in such patients early in the course of disease
requires separate evaluation.
Several recent studies have examined the impact
of anti-TNF agents on radiographic changes in AS
(32,33). This research has not provided convincing evi-
dence of slowing of radiographic progression, despite
anti-TNF treatment for up to 4 years. Explanatory
theories suggest that inflammation and bony progression
are 2 independent pathways, and that suppression of
inflammation may not prevent spinal ankylosis (34). The
impact of TNF blockade on new bone formation in the
spine has been controversial, and it has been suggested
that once inflammation has started, the bony progres-
sion cannot be halted with suppression of TNF alone. If
this is the case, early intervention, when only sacroiliitis
is present, may prevent the development of osteitis at
other sites and subsequent bone growth and fusion at
these sites.
Interestingly, despite the short duration of symp-
toms among patients in this study, 4 patients already met
the modified New York criteria for a diagnosis of AS.
This has been observed in other cohorts of patients with
early inflammatory low back pain (35) and reflects the
fact that some patients do have rapidly progressive
A recent study by Haibel et al (36) examined the
efficacy of adalimumab in the treatment of patients with
axial SpA without radiographically defined sacroiliitis.
Although that study showed efficacy for anti-TNF ther-
apy in this group of patients, there are substantial
differences in the population treated in that study com-
pared with the population treated in the current study.
The mean duration of symptoms in the patients receiv-
Page 7
ing active treatment in the study by Haibel et al (7 years
[range 2–16 years]) was significantly longer than that in
our cohort and cannot really be regarded as representing
early disease. The inclusion criteria for the study by
Haibel et al required the presence of 2 of the following
3 features: inflammatory back pain, HLA–B27 positivity,
and bone edema on MRI. Of the patients treated with
adalimumab in that study, only 14% had the combina-
tion of HLA–B27 positivity and abnormal MRI results.
The study population had a relatively high proportion of
female patients (59%) and a lower prevalence of HLA–
B27 positivity (59%), which is consistent with an undif-
ferentiated SpA cohort rather than an AS cohort. For
these reasons, we believe that the study by Haibel and
colleagues represents treatment of a heterogeneous
group of patients with SpA, many of whom would not be
expected to experience progression to AS. We believe
that patients in our cohort, all of whom were HLA–B27
positive and had abnormal MRI results, are more rep-
resentative of those with early AS.
In conclusion, this study is the first to demon-
strate that infliximab is effective for reducing clinical and
imaging evidence of disease activity in a cohort of
patients in whom progression to radiographic AS is
highly likely. The findings of this study highlight the
need for a diagnosis of AS that is not based on radio-
graphic criteria and suggest that there is a place for
anti-TNF therapy in early axial SpA. However, because
SpA occurs in young people, and the long-term risks of
malignancy following anti-TNF therapy are currently
Figure 1. Magnetic resonance images of the sacroiliac joints of a patient before (A) and after (B) receiving
infliximab therapy. The extensive bone marrow edema that was observed in both sacroiliac joints before
treatment was resolved in the posttreatment scan.
Page 8
unknown, a careful consideration of potential risks and
benefits should be made before beginning anti-TNF
therapy for any patient. Further research is needed to
determine whether this early treatment will halt radio-
graphic progression at the sacroiliac joints and else-
where. If early treatment of axial SpA will also prevent
loss of work participation and result in sustained im-
provement in the quality of life, these patients merit
early intervention.
Dr. Emery had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy of the
data analysis.
Study design. Barkham, O'Connor, Fraser, Cawkwell, Emery.
Acquisition of data. Barkham, Keen, Coates, Fraser, Cawkwell,
Bennett, Emery.
Analysis and interpretation of data. Barkham, Keen, Coates,
O'Connor, Hensor, McGonagle, Emery.
Manuscript preparation. Barkham, Keen, Coates, McGonagle,
Statistical analysis. Hensor.
Radiographic scoring. Bennett.
Centocor had no role in the study design or in the collection,
analysis, or interpretation of the data, the writing of the manuscript, or
the decision to submit the manuscript for publication. Publication of
this article was not contingent upon approval by Centocor.
1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler
A, et al. Prevalence of spondylarthropathies in HLA–B27 positive
and negative blood donors. Arthritis Rheum 1998;41:58–67.
2. Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan
AM, et al. The unmet need for anti-tumour necrosis factor
(anti-TNF) therapy in ankylosing spondylitis. Rheumatology
(Oxford) 2005;44:1277–81.
3. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy
of etanercept in the treatment of the entheseal pathology in
resistant spondylarthropathy: a clinical and magnetic resonance
imaging study. Arthritis Rheum 2001;44:2112–7.
4. Van der Linden S, Valkenburg HA, Cats A. Evaluation of
diagnostic criteria for ankylosing spondylitis: a proposal for mod-
ification of the New York criteria. Arthritis Rheum 1984;27:361–8.
5. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S,
Braun J. Age at disease onset and diagnosis delay in HLA-B27
negative vs. positive patients with ankylosing spondylitis. Rheuma-
tol Int 2003;23:61–6.
6. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use
of dynamic magnetic resonance imaging with fast imaging in the
detection of early and advanced sacroiliitis in spondylarthropathy
patients. Arthritis Rheum 1994;37:1039–45.
7. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm
B, et al. Quantitative analyses of sacroiliac biopsies in spondylo-
arthropathies: T cells and macrophages predominate in early and
active sacroiliitis—cellularity correlates with the degree of en-
hancement detected by magnetic resonance imaging. Ann Rheum
Dis 2000;59:135–40.
8. Marzo-Ortega H, O'Connor P, Emery P, McGonagle D. Sacroiliac
joint biopsies in early sacroiliitis. Rheumatology (Oxford) 2007;46:
9. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection
of sacroiliitis on magnetic resonance imaging and subsequent
development of sacroiliitis on plain radiography: a prospective,
longitudinal study. J Rheumatol 1999;26:1953–8.
10. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a
screening test for ankylosing spondylitis. JAMA 1977;237:2613–4.
11. Gran JT. An epidemiological survey of the signs and symptoms of
ankylosing spondylitis. Clin Rheumatol 1985;4:161–9.
12. Underwood MR, Dawes P. Inflammatory back pain in primary
care. Br J Rheumatol 1995;34:1074–7.
13. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory
back pain in ankylosing spondylitis: a reassessment of the clinical
history for application as classification and diagnostic criteria.
Arthritis Rheum 2006;54:569–78.
14. Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H,
Veys E, et al. Clinical relevance of C-reactive protein in axial
involvement of ankylosing spondylitis. J Rheumatol 1999;26:
15. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M,
de Vlam K, Mielants H, et al. Relative value of erythrocyte
sedimentation rate and C-reactive protein in assessment of disease
activity in ankylosing spondylitis. J Rheumatol 1999;26:980–4.
16. Freeston J, Barkham N, Hensor E, Emery P, Fraser A. Ankylosing
spondylitis, HLA-B27 positivity and the need for biologic thera-
pies. Joint Bone Spine 2007. E-pub ahead of print.
17. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How
to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:
18. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al.
Treatment of active ankylosing spondylitis with infliximab: a
randomised controlled multicentre trial. Lancet 2002;359:1187–93.
19. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing
spondylitis by inhibition of tumor necrosis factor ?. N Engl J Med
20. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K,
Williamson P, et al, and the Ankylosing Spondylitis Study for the
Evaluation of Recombinant Infliximab Therapy Study Group.
Efficacy and safety of infliximab in patients with ankylosing
spondylitis: results of a randomized, placebo-controlled trial
(ASSERT). Arthritis Rheum 2005;52:582–91.
21. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA,
Braun J, et al. Efficacy and safety of adalimumab in patients
with ankylosing spondylitis: results of a multicenter, randomized,
double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:
22. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G,
Hensor E, O'Connor P, et al. Infliximab in combination with
methotrexate in active ankylosing spondylitis: a clinical and imag-
ing study. Ann Rheum Dis 2005;64:1568–75.
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P,
Calin A. A new approach to defining disease status in ankylosing
spondylitis: the Bath Ankylosing Spondylitis Disease Activity
Index. J Rheumatol 1994;21:2286–91.
24. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie
P, et al. A new approach to defining functional ability in ankylos-
ing spondylitis: the development of the Bath Ankylosing Spondy-
litis Functional Index. J Rheumatol 1994;21:2281–5.
25. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP.
Assessment of patient satisfaction in activities of daily living using
a modified Stanford Health Assessment Questionnaire. Arthritis
Rheum 1983;26:1346–53.
26. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS,
Kay LJ, et al. Development of the ASQoL: a quality of life
instrument specific to ankylosing spondylitis. Ann Rheum Dis
Page 9
27. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D,
Braun J. Development and preselection of criteria for short term
improvement after anti-TNF ? treatment in ankylosing spondylitis.
Ann Rheum Dis 2004;63:1438–44.
28. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados
M. Ankylosing Spondylitis Assessment Group preliminary defini-
tion of short-term improvement in ankylosing spondylitis. Arthritis
Rheum 2001;44:1876–86.
29. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing
J, et al. Magnetic resonance imaging examinations of the spine in
patients with ankylosing spondylitis, before and after successful
therapy with infliximab: evaluation of a new scoring system.
Arthritis Rheum 2003;48:1126–36.
30. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of
a major clinical response (BASDAI 50) to tumour necrosis factor
? blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:
31. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados
M, et al, for the ASAS Working Group. International ASAS
consensus statement for the use of anti-tumour necrosis factor
agents in patients with ankylosing spondylitis. Ann Rheum Dis
32. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper
J, et al. Radiographic progression in patients with ankylosing
spondylitis after 4 yrs of treatment with the anti-TNF-? antibody
infliximab. Rheumatology (Oxford) 2007;46:1450–3.
33. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J.
Radiographic progression in patients with ankylosing spondylitis
after 2 years of treatment with the tumour necrosis factor ?
antibody infliximab. Ann Rheum Dis 2005;64:1462–6.
34. Lories RJ, Derese I, De Bari C, Luyten FP. Evidence for uncou-
pling of inflammation and joint remodeling in a mouse model of
spondylarthritis. Arthritis Rheum 2007;56:489–97.
35. Puhakka KB, Jurik AG, Schiottz-Christensen B, Hansen GV,
Egund N, Christiansen JV, et al. MRI abnormalities of sacroiliac
joints in early spondylarthropathy: a 1-year follow-up study. Scand
J Rheumatol 2004;33:332–8.
36. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL,
Kupper H, et al. Efficacy of adalimumab in the treatment of axial
spondylarthritis without radiographically defined sacroiliitis: re-
sults of a twelve-week randomized, double-blind, placebo-con-
trolled trial followed by an open-label extension up to week
fifty-two. Arthritis Rheum 2008;58:1981–91.


text:
Eccleston, ChristopherOverview
Publication Timeline
Most widely held works by
Christopher Eccleston
by Shekhar Kapur
86 editions published between 1998 and 2012 in 7 languages and held by 3,151 WorldCat member libraries worldwide Queen Elizabeth I must learn to weigh her counsel carefully and ignore her private yearnings if she is to keep her crown--and her head. A thriller of intrigue in the court of one of history's greatest monarchs
The others
by Alejandro Amenábar
31 editions published between 2001 and 2011 in 3 languages and held by 1,849 WorldCat member libraries worldwide A devoutly religious mother of two ailing children has moved with her family to a mansion on the English coast. Her two children both suffer from a rare photosensitivity disease that renders them extremely vulnerable to sunlight, prompting the rule of having only one door open in the house at a time. When one of the children claims to see ghosts, Grace at first believes her newly arrived family of eccentric servants to be responsible, but chilling events and visions soon lead her to believe that something supernatural is indeed going on
28 days later
by Danny Boyle
38 editions published between 2002 and 2009 in English and German and held by 1,759 WorldCat member libraries worldwide An infirmary patient wakes up from a coma to an empty room ... in a vacant hospital ... in a deserted city. A powerful virus, which locks victims into a permanent state of murderous rage, has transformed the world around him into a seemingly desolate wasteland. Now a handful of survivors must fight to stay alive, unaware that the worst is yet to come
5 editions published between 2013 and 2014 in English and held by 1,493 WorldCat member libraries worldwide Worlds collide when a powerful ancient enemy threatens to plunge the cosmos into eternal darkness. Thor fights to restore order across the cosmos, but an ancient race led by the vengeful Malekith returns to plunge the universe back into darkness. Faced with an enemy that even Odin and Asgard cannot withstand, Thor must embark on his most perilous and personal journey yet. Now, reunited with Jane Foster, and forced to forge an alliance with his treacherous brother Loki, Thor embarks on a perilous personal quest to save both Earth and Asgard from destruction
G.I. Joe., the rise of Cobra
by Stephen Sommers
10 editions published between 2009 and 2010 in English and Turkish and held by 1,411 WorldCat member libraries worldwide Weapons expert James McCullen has created a nanotechnology-based weapon capable of destroying an entire city. His company MARS sells four warheads to NATO, and the U.S. Army is tasked with delivering the warheads. Duke and Ripcord are delivering the warheads when they are ambushed by the Baroness. The two are rescued by Scarlett, Snake Eyes and Heavy Duty. They take the warheads to the G.I. Joe's command center, rendezvousing with General Hawk. McCullen is revealed to be using the same nanotechnology to build an army of soldiers with the aid of the Doctor
by Mira Nair
9 editions published between 2009 and 2010 in English and held by 1,360 WorldCat member libraries worldwide Kansas-born girl, Amelia Earhart discovers the thrill of aviation at age 23. Within 12 years she goes on to win the Distinguished Flying Cross for being the first woman to pilot a plane solo across the Atlantic Ocean. Amelia and her husband/business partner George Putnam have an enduring marriage that could not be broken by her determination to fly, nor her passionate affair with Gene Vidal. At age 39, she sets out on an attempt to circumnavigate the globe, an adventure that catapults her into aviation myth
The seeker the dark is rising
8 editions published between 2007 and 2008 in English and held by 1,173 WorldCat member libraries worldwide During Christmas break from school, a seemingly typical teenager discovers that he is anything but ordinary. As the seventh son of a seventh son, Will Stanton is The Seeker - a chosen warrior destined to restore the delicate earthly balance between Light and Dark. Guided by ancient protectors of the Light, young Will must travel through time to gather the hidden signs that hold the ultimate power to protect the world
Doctor Who
8 editions published between 2006 and 2013 in English and held by 814 WorldCat member libraries worldwide In the new Doctor Who series, London shop assistant Rose Tyler embarks on adventures through time and space with a mysterious alien known as "The Doctor," encountering strange lifeforms and protecting the Earth from alien invaders
Shallow grave
by Danny Boyle
48 editions published between 1984 and 2014 in 4 languages and held by 794 WorldCat member libraries worldwide When three friends find their new roommate dead and a suitcase full of money under his bed, they have no trouble deciding how to dispose of the cash, but the body is a different story. Their troubles are compounded when they meet the men who come to retrieve the money
Gone in sixty seconds
by Dominic Sena
2 editions published between 2000 and 2005 in English and held by 668 WorldCat member libraries worldwide A retired master car thief must come back to the industry and steal 50 cars with his crew in one night to save his brother's life
by Andrew Davies
15 editions published between 2001 and 2011 in English and German and held by 551 WorldCat member libraries worldwide A version of Shakespeare's drama about Othello, and the jealousy of his mentor Jago, set in modern day London
by David Cronenberg
6 editions published between 1999 and 2002 in English and held by 469 WorldCat member libraries worldwide A designer of a virtual reality game is hunted by an assassin intent on killing her and destroying her creation
by Michael Winterbottom
52 editions published between 1995 and 2014 in 7 languages and held by 408 WorldCat member libraries worldwide A working class stonemason has scholarly ambitions that are sidetracked by an unhappy marriage and an obsession with his cousin. He leaves his wife to live with his cousin with tragic consequences
A Price above rubies
by Boaz Yakin
9 editions published between 1997 and 2011 in English and held by 369 WorldCat member libraries worldwide Renee Zellweger is Sonia, a young woman who must decide between her desire for independence and the security of the perfect life she knows
Doctor Who
26 editions published between 2005 and 2013 in English and held by 358 WorldCat member libraries worldwide The Doctor and his companion Rose travel around the universe and through time to battle Daleks and other evil aliens
Lennon naked
7 editions published in 2010 in English and held by 308 WorldCat member libraries worldwide One of the most enduring and enigmatic figures of the 20th century, John Lennon. One quarter of the 'Fab Four, ' peace activist, visual artist, and author, he was a man whose personal life was never short on drama, intrigue, and, eventually, conspiracy. Thirty years after his death, this film presents an inside look at the hugely popular musician as he moved from a Beatle to an icon
The Borrowers
by Peter Hewitt
3 editions published between 2011 and 2014 in English and held by 281 WorldCat member libraries worldwide Arrietty Clock is a head-strong teenage Borrower whose parents, Pod and Homily, are terrified of the 'Human Beans' who live above them. Desperate for freedom and adventure, Arrietty sneaks out one night and befriends a lonely boy who lives upstairs. But Arrietty's adventure inadvertently reveals her family's existence to the scheming scientist Professor Mildeye, forcing them to go on the run into the big bad world
2 editions published in 2003 in English and held by 249 WorldCat member libraries worldwide Fitz is an addicted gambler, a heavy drinker, and a brilliant, if deeply flawed criminal psychologist. Follow Fitz as he investigates an accused commuter train killer with amnesia, a couple who share love and murder, and the killing of a young boy that shakes a community to its core
Let him have it
17 editions published between 1991 and 2010 in English and held by 236 WorldCat member libraries worldwide Set in the gritty, post-war world of 1950's London, American movie gangsters are the reigning heroes of aimless young toughs that roam the streets. A robbery turns to murder and a simple-minded teenager finds himself facing a death sentence for a crime he did not commit
Gone in sixty seconds
1 edition published in 2005 in English and held by 231 WorldCat member libraries worldwide Legendary car booster Memphis Raines thought he'd left the fast lane behind until he's forced out of retirement in a do or die effort to save his kid brother more
Audience Level
Related Identities
Associated Subjects
Adventure and adventurers Air pilots' spouses Ambushes and surprises Anger Attempted assassination Automobile theft Avarice Borrowers (Fictitious characters) Brothers Dead Distinguished Flying Cross (Medal) Doctor Who (Fictitious character) Elizabeth (Motion picture) Enemies England Friendship Ghost plays Good and evil Great Britain Human-alien encounters Immortalism Interplanetary voyages Italy--Venice Jealousy Kings and rulers Kings and rulers--Succession Man-woman relationships Military bases Military weapons Mother and child Muslims Nanotechnology Othello (Fictitious character) Photosensitivity disorders Political science Queens Roommates Scotland Scotland--Edinburgh Signs and symbols Soldiers Spirits Survivalism Thor (Norse deity) Time travel United States Virtual reality Viruses Weapons industry Women air pilots
Alternative Names
Eccleston, Christopher 1964-
German (21) Spanish (8) French (4) Turkish (2) Italian (2) Multiple languages (2) Elamite (1) Covers


text:
No graded pricing is available for this item.
There is no box for this item.
Item |
Set: 1998-99 Black Diamond Diamond Dominance |
Player: Kemp, Shawn |
Team: Cleveland Cavaliers |
Sport: Basketball |
Brand: Black Diamond |
Manufacturer: Upper Deck Co. |
This item is not currently in stock on the Beckett Marketplace. Please check back again soon!
No users have to trade for this.
Username | Qty | Condition | |
crimedawg47 | 1 | Near Mint/Mint | Start xChange |
Coming soon...


text:
In this fight from West Coast Fighting Championship "Bruvado Bash" which took place on January 7th 2012, Lightweights Keni "Man on Fire" Renta and Anthony "Goldie" Charnell faced off in the WFC cage. You can see Keni's next fight September 8th at the Yuba-Sutter fairgrounds in Yuba City, CA For more information, please visit: westcoastfighting.com facebook.com/westcoastfighting twitter.com/wfc_mma watch video >>
Fedor "The Last Emperor" Emelianenko lost to Antonio "Bigfoot" via TKO from a swollen shut right eye. Steven Bash is Fedor's attorney and he tells us how Fedor was feeling after the fight and whether or not his talk of retirement was based on emotion or was serious. Intro Sound Clip: Bliss n Eso - People on it (feat Xzibit) watch video >>


text:
Credit Counselling Canada is a valuable resource for information about credit-related topics, trends and best practices including credit and debt consolidation in Canada. We are happy to share information with the media and public at large, and will respond to any inquiries or requests as quickly as possible. For additional information contact Pat White, Executive Director directly at: email@example.com
Monday, February 09, 2015 by: Guest Blogger
Tuesday, January 27, 2015 by: Credit Counselling Canada
Tuesday, January 20, 2015 by: Carol Fraser
Thursday, November 27, 2014 by: Guest Blogger
Wednesday, November 26, 2014 by: Guest Blogger


text:
US 20030107749 A1 Abstract An in-vehicle printing system that provides an in-vehicle mounted printer operably connected to a host-computing device such as the vehicle's telematics system or a personal computer.
Claims(20) 1. An in-vehicle information printing system for an occupant in a vehicle comprising:
a printer operably received within the vehicle; and, a telematics system providing information to the occupant, said telematics system serving as a host device for commanding the printer; such that said information from the telematics system may be printed on a print medium operably connected to the printer to thereby allow the vehicle occupant to display said information in printed format. 2. The in-vehicle information printing system for an occupant in a vehicle of
3. The in-vehicle information printing system for an occupant in a vehicle of
4. The in-vehicle information printing system for an occupant in a vehicle of
5. The in-vehicle information printing system for an occupant in a vehicle of
6. The in-vehicle information printing system for an occupant in a vehicle of
7. The in-vehicle information printing system for an occupant in a vehicle of
8. A method for displaying information from a telematics system, the telematics system able to wirelessly transmit information from a remote location to the vehicle, the vehicle having a passenger compartment with a plurality of passenger seats therein, each said passenger seat having a seating area, said method for displaying information comprising the steps of:
securing a printer within the passenger compartment such that the seating area of each passenger seat within the vehicle is not blocked by any portion of the printer; operably connecting the telematics system to the printer; receiving information through the telematics system; printing the information on a print medium operably secured to the in-vehicle printer. 9. The method for displaying information in a vehicle of
10. An in-vehicle printer comprising:
a printer operably connected to a host device, said host device commanding the printer; and, a vehicle having a chamber for receiving said printer and a passenger seat therein, said passenger seat having a passenger seating area; wherein said printer is operably secured within said chamber such that said printer does not occupying any portion of said seating area. 11. The in-vehicle printer of
12. The in-vehicle printer of
13. The in-vehicle printer of
14. The in-vehicle printer of
15. The in-vehicle printer of
16. The in-vehicle printer of
17. The in-vehicle printer of
18. The in-vehicle printer of
19. The in-vehicle printer of
20. The in-vehicle printer of
Description [0001] This invention relates to a printer embedded in a vehicle to facilitate a variety of printing applications such as telematics system support and on-site printing from a portable personal computer. [0002] Vehicle telematics system; which combine telecommunications equipment with on-board and remote computers to facilitate operation and use of a vehicle, are gaining in popularity. One known type of vehicle telematics system uses an in-vehicle computer, a global positioning satellite (GPS) transceiver, and a wireless communication system for automatic roadside assistance and remote vehicle locating and diagnostics. Such vehicle telematics systems are commercially available. For example, the OnStar Corporation of Troy, Mich., which is a wholly-owned subsidiary of the General Motors Corporation, sells such a system under the trademark ONSTAR. [0003] Most of the communication between the passenger and the existing telematics system is transmitted audibly, usually using a microphone in the vehicle and the speakers of the vehicle's sound system. In practice, this audible-only form of communication is inefficient and time consuming for performing some functions For example, if a vehicle occupant would like directions to a particular location, they activate the telematics system to contact a remote fixed center, usually through a wireless communication system component of the telematics system, such as a cell phone. An operator receives the call from the vehicle along with appropriate positioning information from the vehicle through the GPS technology component of the telematics system. The operator then compares the location of the vehicle with the desired location of the driver and then provides the driving directions to the vehicle occupant by speaking to the occupant over the cell phone. The occupant then must remember each step of the directions, or write them down as they are audibly provided to him by the operator. Accordingly, the vehicle occupant often forgets the provided directions, or worse when the vehicle occupant is the driver, he may be distracted while driving by attempting to write down the information provided by the operator. [0004] In addition to the current features offered by vehicle telematics systems, new generation vehicle telematics systems are being developed that allow vehicle occupants to maintain further contact with their fixed computing and communication systems while on the road. For example, these new generation vehicle telematics systems will allow vehicle occupants to send and receive email and browse a world wide computing network, such as the Internet, while traveling in the vehicle. However, the current audio-only form of communication between the vehicle occupants and the telematics system, severely limits the usefulness of these additional features. For example, few vehicle occupants would welcome having a remote operator read the vehicle occupant's personal email to them over the cell phone component of the telematics system. Similarly, information found by the vehicle occupant while searching a worldwide computing network is difficult to retrieve and comprehend using only audio input. [0005] To date, printer use in vehicles has focused primarily on making the printers portable to support laptop computer operations. For example, U.S. Pat. No. 6,273,310 to Gregory discloses a portable arm rest-type console for receiving a laptop computer and printer therein. The console is designed so that a driver can operate the laptop computer, and print materials from the computer as needed while driving. The console itself is detachably secured to the vehicle and occupies at least one seat in the vehicle. The printer is slidably received within the console such that to operate the printer, the user must open an access door in the console and slide the printer over the front, right passenger seat of the vehicle. The console also includes carrying straps for moving the console from place to place. Similar structures are disclosed in U.S. Pat. No. 5,966,285 to Demtchouk and U.S. Pat. No. 6,135,546, both of which provide removable computer workstations that rest on vehicle seats. [0006] These types of detachable computer workstations have several limitations. For example, they are bulky, heavy, and relatively expensive. They also occupy at least one seat in the vehicle, thereby reducing the seating capacity of the vehicle, and they do not improve the communication between the vehicle's occupants and the vehicle's telematics system. [0007] Accordingly, despite the known use of printers in vehicles, there remains a need for an in-vehicle printing system that provides an in-vehicle mounted printer operably connected to a host-computing device, such as the vehicle's telematics system or a personal computer. Preferably, that printer is secured within the vehicle such that it does not reduce the available seating capacity of the vehicle and it is concealed when not in use. In addition to other benefits that will become apparent in the following disclosure, the present invention fulfills these needs. [0008] The present invention is an in-vehicle printing system that provides a printer operably secured and concealed within an existing component of the vehicle, such as the front passenger seat. The printer is preferably in communication with the vehicle's telematics system. [0009]FIG. 1 is a partial, isometric view of a vehicle having a seat therein containing a printer in accordance with an embodiment of the present invention. [0010]FIG. 2 is an isometric view of the printer of FIG. 1. [0011]FIG. 3 is an enlarged back, plan view of the vehicle seat of FIG. 1. [0012]FIG. 4 is a side view of the seat of FIG. 2 showing a possible orientation of the printer therein. [0013]FIG. 5 is a side view of the seat of FIG. 2 showing an alternative possible orientation of the printer. [0014]FIG. 6 is a block diagram of an in-vehicle printing system in accordance with an embodiment of the present invention. [0015] An in-vehicle printing system 18 (FIG. 6) having a printer 20 operably secured in a vehicle 22 and operably connected to the vehicle's telematics system 24 and/or a personal computer 52 is disclosed in FIGS. 1-6. [0016] A. Printer Assembly [0017] The printer 20 is preferably a conventional printer that has been adapted for installation in the vehicle. One known type of printer 20 having the overall dimensions to be readily secured within a vehicle as described is an inkjet printer manufactured and sold by the Hewlett-Packard Corporation of Palo Alto, Calif. under the trademark HP DESKJET 350C. The inkjet printer 20, shown in FIG. 2, includes a chassis 26, a print medium handling system 28 for supplying sheets of print media to the printer 20, and a movable print carriage 30 for moving one or more printheads 32 relative to the print medium at a print zone 34. The print media may be any type of suitable sheet material, such as paper, card-stock, transparencies, mylar, foils, and the like, but for convenience, the illustrated embodiment is described using paper as the print medium. The print medium handling system 28 moves the print media into the print zone 34 from a feed tray 35 to an output tray 36, for instance, using a series of conventional motor-driven rollers (not shown). [0018] In the print zone 34, the media sheets receive ink from a printhead 32. Each printhead 32 has bottom surface comprising an orifice plate with a plurality of nozzles formed therethrough in a manner well known to those skilled in the art. The illustrated printheads 32 are thermal inkjet printheads, although other types of printheads may be used, such as piezoelectric printheads. The printheads 32 typically include a plurality of resistors that are associated with the nozzles. Upon energizing a selected resistor, a bubble of gas is formed ejecting a droplet of ink from the nozzle and onto a sheet of paper in the print zone 34 under the nozzle. [0019] The printheads 32 are transported by the carriage 30, which may be driven by a conventional drive belt/pulley and motor arrangement (not shown) along a guide rod 40. The guide rod 40 defines a scanning direction or scanning axis along which the printheads 32 traverse over the print zone 34. The printheads 32 selectively deposit one or more ink droplets on a print media page located in the print zone 34 in accordance with instructions received via a conductor strip from a printer controller (not shown), such as a microprocessor which may be located within chassis 26. The controller may receive an instruction signal from a host device 50 (FIG. 6), which is typically a computer, such as a personal computer 52. Preferably, the host device 50 also includes the vehicle's telematics system 24. [0020] The printhead 38 carriage motor (not shown) and the print medium handling system 28 drive motor (not shown) operate in response to the printer controller, which may operate in a manner well known to those skilled in the art. The printer controller may also operate in response to user inputs provided through a keypad 54 (FIG. 2). A monitor 56 coupled to the host computer may be used to display visual information to an operator, such as the printer status or a particular program being run on the computer. Personal computers, their input devices, such as a keyboard and/or a mouse device, and monitors are all well known to those skilled in the art. [0021] B. Printer Mounting [0022] The printer 20 is preferably secured within the passenger compartment 21 of the vehicle 22 such that it does not reduce the available seating capacity of the vehicle 22 and it is concealed when not in use. More preferably, the printer 20 is positioned in the vehicle so as not to distract the driver of the vehicle 22 while driving. [0023] Accordingly, a particularly desirable location for mounting the printer is within a passenger seat 60. More preferably, as best shown in FIGS. 1, and 3-5, the printer 20 is mounted in the seat back 62 of the front passenger seat 60 of the vehicle 22 so that the printed material is expelled from the back 68 of the front passenger seat 60. [0024] The seat back 62 preferably includes a chamber 64 sized to receive the printer 20 and feed tray 35. The chamber 64 includes a latchable, access door 66 that is preferably pivotally secured to the passenger seat 60 thereby defining a closed position 70 shown in FIGS. 1, 3, and 4, and an open position 72 shown in FIG. 5. As best shown in FIG. 1, all available seats in the vehicle are available and unblocked when the access door 66 is in its closed position 70. [0025] The back 68 of the passenger seat 60 includes an inlet slot 74 for receiving paper into the feed tray 35, and an exit slot 76 for allowing printed paper to be expelled from the chamber 64 after passing through the printer 20. With the access door 66 in its closed position 70, a paper path is defined by arrows 78 such that sheets of paper travel through the inlet slot 74 to the feed tray 35, where it then travels through the printer 20 and out the exit slot 76. [0026] The output tray 36 is preferably secured to the access door 66, adjacent to the exit slot 76 for compiling and neatly storing printed paper expelled through the exit slot 76 from the printer 20. More preferably, this output tray 36 is pivotally secured to the access door 66 such that it may pivot out of the way when not in use as shown in broken lines in FIG. 4. [0027] Preferably, the printer 20 is operably secured to the access door 66 such that the internal printer components are easily accessible when the access door 66 is in its open position 72 as shown in FIG. 5. Alternatively, the printer 20 may be secured to the passenger seat 60 within the chamber 64, with access to the printer components being provided by separate access door (not shown) in the chassis 26. Vibration isolators (not shown) preferably extend between the printer 20 and chamber to help isolate the printer 20 from vibrations while the vehicle 22 travels. [0028] Similarly, the feed tray 35 is preferably easily accessible when the access door 66 is in its open position 72, thereby allowing paper jams and like in the feed tray 35 to be easily cleared. One known way to provide an easy access feed tray 35 is shown in FIGS. 4 and 5. As best shown in FIG. 4, the feed tray 35 preferably includes a forward panel 82 and a rearward panel 84 that are spaced apart from each other and aligned substantially parallel with each other when the access door 66 is placed in its closed position 70. The distance 86 between the two panels 82, 84 defines a storage area 88 for receiving a stack of sheets of paper, said sheets being fed one at a time to the printer 20 using known technology. [0029] The forward panel 82 extends from the lower lip 90 of the inlet slot 74 in the access door 66 to the inlet portion 92 of the printer. When the access door 66 is in its closed position 70, the rearward panel 84 extends from the upper lip 96 of the inlet slot 74 in the access door 66 to the inlet portion 92 of the printer 20 as shown in FIG. 4. The rearward panel 84 is preferably pivotally secured to the printer 20 and biased to a position away from the access door 66 such that when the access door is in its open position 72, the rearward panel 84 pivots away from the forward panel 82 in the direction of arrow 98 (FIG. 5) thereby providing easy access to the feed tray 35. It can be appreciated by one skilled in the art, that moving the access door 66 to its closed position 70 urges the rearward panel 84 of the feed tray 35 in the direction of arrow 100 (FIG. 5) to contact the passenger seat 60 as shown, thereby ultimately positioning the forward and rearward panels 82, 84 substantially parallel with each other as shown in FIG. 4 and defining the feed tray 35 as previously described. [0030] C. Printer Communication [0031]FIG. 6 shows an exemplar block diagram of the printer 20 being connected to a plurality of host devices 50 including a personal computer 52 and the vehicle's telematics system 24. [0032] Preferably, the printer 20 is in electrical communication with an existing power source 102 on the vehicle 22, such as the vehicles' battery or electrical system. The preferred location of the printer 20 in the front passenger seat 60 allows the printer 20 to be easily connected to an existing power source 102, such as power lines typically running to the passenger seat 60 to power electrical seat movement actuators (not shown) or seat heaters (not shown) imbedded within the passenger seat 60. [0033] The vehicle's telematics system 24 is known in the art. One known type of vehicle telematics system uses automobile systems, a global positioning satellite (GPS) technology, and other wireless communication systems for automatic roadside assistance and remote vehicle locating and diagnostics. One known functioning vehicle telematics system is sold by the OnStar Corporation of Troy, Mich. under the trademark ONSTAR. [0034] Placing the printer 20 in communication with the vehicle's telematics system 24 allows a variety of information to be printed for the vehicle occupant's convenience. For example, vehicle occupants can receive facsimile transmission, print pages of information displayed on a world-wide network, such as the Internet, and print their e-mail while traveling in the vehicle. Similarly, current information provided by the vehicle telematics system 24, such as driving directions, reservation numbers, and the like, may now be sent by a remote operator to the printer 20, thereby allowing the vehicle occupants to print out and read this information more efficiently than attempting to remember it or write it down while driving. Moreover, as the variety of information available to vehicle occupants through vehicle telematics systems increases, the printer 20 will facilitate vehicle occupant's access to and retention of this information. [0035] Preferably, the printer also includes at least one port 104 to detachably secure an auxiliary computing device, such as a personal computer 52, handheld computer (not shown), digital camera (not shown), scanner (not shown), or the like. This port 104 can be a physical connection, such as a printer jack 106 or Universal Serial Bus (�USB�) 108 port, or it can be a wireless port, such as a conventional infrared port 110 or other wireless technology 112, such as the wireless technology currently sold by a variety of manufacturers under the collective trade name BLUE TOOTH. In such case, the auxiliary computer device would include appropriately compatible wireless transmitters and receivers to communicate through the corresponding wireless port connected to the printer 20. In addition, the location of these components within the vehicle can be optimized for the particular auxiliary computing device. For example, the wireless receive can be located within the vehicle dashboard or the like to facilitate connection of an auxiliary computer device while being held by a vehicle occupant in the front seats of the vehicle. Accordingly, the on-board printer can also be used as a conventional printer to support conventional personal computing, scanning, and digital photograph printing operations. [0036] E. Alternative Embodiments [0037] Even though the foregoing description has focused on the installation and operation of an inkjet printer, it can be appreciated that the basic concepts of this invention will work equally well with any other type of printer and associated print-medium installed in the vehicle. Similarly, there need not be a physical connection between the vehicle's telematics system and the printer. Appropriate wireless communications, such as the disclosed infrared (IR) and BLUE TOOTH technologies, could be applied to transmit information between the printer and vehicle telematics system. [0038] Thus, having here described preferred embodiments of the present invention, it is anticipated that other modifications may be made thereto within the scope of the invention by individuals skilled in the art. Thus, although preferred and alternative embodiments of the present invention have been described, it will be appreciated that the spirit and scope of the invention is not limited to those embodiments, but extend to the various modifications and equivalents as defined in the appended claims. Referenced by
Legal Events
Rotate |


text:
Millar College of the Bible
Coordinates: 49°56′9″N 107°27′26″W / 49.93583°N 107.45722°W
Millar College of the Bible (Millar Memorial Bible Institute) |
Established | November 10, 1944 |
Type | Private |
Affiliation | Christian |
Location | Pambrun, Saskatchewan, Canada |
Campus | Rural |
Website | www.millarcollege.ca |
Millar College of the Bible (formally called the Millar Memorial Bible Institute in its act of incorporation) is a post secondary institution established in 1944 in Pambrun, Saskatchewan, Canada.[1] The school is a private nonprofit institution recognized under a private act offering post secondary education.[2]
Originally established as the Millar Memorial Bible Institute by William Dickson and Herbert W. Peeler both of Pambrun and Charles Williamson of Glen Bain, the school was to train workers for Evangelical bodies in Western Canada and overseas.[1]
The campus has 7 main buildings including:[3]
- Administration building
- Dickson Hall (staff/faculty office building)
- Student Centre (with dining hall, chapel, student lounge and library)
- David Pollard Fine Arts Centre (music and drama)
- Gymnasium
- Ladies' residence
- Two men's residences
Also of note:
- Outdoor rink
- Soccer field
The college offers the one year Impact Certificate and the two year Christian Ministry Diploma. The Bachelor of Biblical Studies takes three years to complete and the Bachelor of Arts in Strategic Ministries takes four years.[4]
- ^ a b "Millar College of the Bible being a Private Act Chapter 72 of the Statutes of Saskatchewan, 1944 (Second Session) (effective November 10, 1944) as amended by the Statutes of Saskatchewan, 1990-91, c.02.". Queen's Printer. Retrieved 2011-02-11.
- ^ "Millar College of the Bible". Canadian Information Centre For International Credentials. Retrieved 2011-02-11.
- ^ "New Student Guide". Millar Memorial Bible Institute. Retrieved 2011-02-11.
- ^ "Academic Program". Millar Memorial Bible Institute. Retrieved 2011-02-11.
External links[edit]


text:
Unique vacations
» China unique vacations
China Unique Vacations
We have compiled a list of unqiue vacations in China. If you are interested in any of these unqiue vacations, please contact the operator directly with any questions for ordering free brochures or booking. The list is updated frequently so visit often.
Beijing Volleyball 9 Days Tour
10% off.
Contact Supplier
We'll take care of all the arrangements and provide you with a memorable hockey experience. All you have to do is place the call, let us do the rest.
Read more >>>
USD 780 - 1080 Per person
Beijing Volleyball 7 Days Tour
10% off.
Contact Supplier
We'll take care of all the arrangements and provide you with a memorable volleyball experience. All you have to do is place the call, let us do the rest.
Read more >>>
USD 580 - 880 Per person
Detox and meditation retreat
10% off.
Contact Supplier
Detox and meditation retreat in Yunnan, China.
Read more >>>
USD 800 - 2000 Per person
A Special Chritsmas to Appreciate the Island Scenery in Sanya, Hainan
Contact Supplier
Enjoy a Special Chritsmas to Appreciate the Island Scenery in Sanya, Hainan.
Read more >>>
USD 705 - 1562 Per person
Beijing Evening Tour
Contact Supplier
Enjoy world-famous Chinese acrobatics.
Read more >>>
USD 30 - 100 Per person
Cultural China & Tibet with Yangtze River Cruise
Contact Supplier
This exciting vacation introduces you to the rich history and cultural treasures of China and Tibet as well as the magic of the Yangtze River.
Read more >>>
USD 3863 - 4213 Per person
Search Vacations by Activity:
----- Select Activity -----
All Vacations
Art and Crafts Vacations
Bicycling Vacations
Birding Vacations and Outfitters
Boating and Sailing Vacations
Culture Vacations
Eco Tourism Vacations
Food and Wine Vacations
Golf Vacations
Hiking and Trekking Vacations
Hunting Vacations
Language Study Vacations
Mountain & Rock Climbing Vacations
Photography & Videography Vacations
Railway Vacations
Scuba Diving Vacations
Spiritual Vacations
Sport Vacations
Wildlife Viewing Vacations
advanced search
Specialty Vacations
China Vacations
China Art and Crafts Vacations
China Bicycling Vacations
China Birding Vacations and Outfitters
China Boating and Sailing Vacations
China Culture Vacations
China Eco Tourism Vacations
China Food and Wine Vacations
China Golf Vacations
China Hiking and Trekking Vacations
China Hunting Vacations
Language Study Vacations in China
China Mountain & Rock Climbing Vacations
China Photography & Videography Vacations
China Railway Vacations
China Scuba Diving Vacations
China Spiritual Vacations
China Sport Vacations
China Wildlife Viewing Vacations
Central America
Middle East
North America
South America


text:
Tyler ISD votes unanimously for a bond election in Nov
POSTED: Tuesday, August 24, 2010 - 5:14pm
UPDATED: Tuesday, August 24, 2010 - 5:45pm
TYLER - Tyler ISD votes to have a bond election this coming November. It calls for a vote on a 89 million dollar bond package that would help pay for a new middle school and two elementary schools. Joann Fleming, the executive director for Grassroots America we the people says local government needs to get on the same page as tax payers and cut spending. Here's the updated full story.
Jessica Wilson / KETKnbc.com


text:
Hi all, So I have a bottling problem. I cold crash all of the beer I brew pre-bottling and that tends to work fine, good carbonation. The last few beers I have made have been with the CL-50 yeast (love it), which when crashed really settles out. In the future I will repitch some dry yeast for bottling but my question is what to do with the first batch sitting flat in bottles? Do I dump it, empty the bottles back into a carboy and repitch bottling yeast? Any advice from anyone who has gone through this before would be great. Thanks
If you are going to empty them into a carboy make sure you pour down the side to minimize oxygen exposure. I tried this once and while the beer wasn't ruined, it didn't quite have the same flavor as earlier batches. I had a brew buddy bottle 5 gallons that had sat for at least 3 months in his secondary. After bottling it never did carbonate. What we did on his case was crack open the bottles and add a SMALL pinch of dry yeast (no more than ten little granules). After recapping he let them condition for a few weeks. This worked beautifully. I had tasted one prior to this and wasn't able to really tell a difference after.
Perfect, this was the info I was looking for. A pinch of dry yeast per bottle, I knew I would put that Nottingham to good use. You may have saved my first tasty wet hop ale. Pat


text:
Archive - Oct 2012Perdue issues State of Emergency ahead of SandySubmitted by WWAY on Fri, 10/26/2012 - 3:53pm.READ MORE:
Gov. Bev Perdue has issued a State of Emergency for eastern North Carolina as Hurricane Sandy heads north toward the coast.
The declaration goes into effect Saturday for 33 eastern North Carolina counties. A tropical storm warning is in effect from Nags Head to the South Carolina border.
Full story... » UNC releases documents as part of settlementSubmitted by WWAY on Fri, 10/26/2012 - 3:50pm.READ MORE:
The University of North Carolina at Chapel Hill has released documents outlining violations by football players for receiving improper benefits as part of a settlement to end a public-records fight over information from an NCAA investigation into the program.
Full story... » CFCC hosts fuel-efficient car showSubmitted by IE on Fri, 10/26/2012 - 3:47pm.READ MORE:
Cape Fear Community College hosted a somewhat different car show today.
Instead of powerful engines and custom paint jobs, the vehicles were judged on economical and environmental performance.
Full story... » Children's Museum hosts early trick-or-treatingSubmitted by IE on Fri, 10/26/2012 - 3:43pm.READ MORE:
Hurricane Sandy isn't going to ruin the weekend for some tots around the area. Halloween started a little early for some younger princesses and super heroes this morning at the Children's Museum of Wilmington.
Full story... » Oklahoma State takes first round lead in Landfall TraditionSubmitted by John Rendleman on Fri, 10/26/2012 - 3:25pm.READ MORE:
Update: The first round of the 11th Annual Landfall Tradition is complete. The second round started on Saturday, but the golfers were unable to finish the second round due to foul weather. Play on Sunday is tentatively set to begin at 9:30 a.m.
Full story... » Cape Fear Fair & Expo keeping eye on Sandy forecastSubmitted by WWAY on Fri, 10/26/2012 - 3:23pm.READ MORE:
Organizers at the Cape Fear Fair & Expo are keeping a close watch on how Hurricane Sandy impacts the weather this weekend. For now, though, the fair is scheduled to be open tonight for Midnight Madness, which runs until 2 a.m.
Full story... » More details on Figure 8 drowningSubmitted by StarNewsOnline.com on Fri, 10/26/2012 - 12:22pm.READ MORE:
Previously unreported details released during an interview with the lead investigator, R.W. Beasley, on Thursday provides the clearest explanation yet for how Benjamin Williamson died in what authorities ruled an accidental death.
Full story... » New trial set for NC man in woman's deathSubmitted by Allyson Lorick on Fri, 10/26/2012 - 10:06am.READ MORE:
A judge in Gastonia says the jurors will be chosen from another county for the retrial for a North Carolina man in the death of a woman whose body was found in South Carolina.
Full story... » 2 NC bands chosen for London New Year's paradeSubmitted by Allyson Lorick on Fri, 10/26/2012 - 10:03am.READ MORE:
Two high school bands from North Carolina will be taking part in the New Year's Day parade in London in 2014.
Full story... » |